20.12.2018 • News • Azelis • Mergers & Acquisitions (M&A) • Fine Chemicals & Specialty Chemicals

Azelis to Take Italy’s Deafarma

Azelis to Take Italy’s Deafarma (c) Azelis
Azelis to Take Italy’s Deafarma (c) Azelis

Leading specialty chemicals and food ingredients distributor Azelis is in exclusive talks to acquire Deafarma, an Italian distributor of APIs.

The Milan-based company also offers a range of services such as searching for new APIs, assistance with regulatory affairs and new pharmaceutical dossier support.

Commenting on the deal, Marco Gerosa, regional managing director Italy at Azelis, said: “There is an excellent strategic fit that supports our further growth in the region, allowing us to provide an improved product offering and customer reach on one side, while making us more attractive to our existing principals on the other. Our aim is to offer our customers in Italy the full pharma range of products.”

The transaction is expected to complete in the first quarter of 2019.

Azelis noted that the acquisition illustrates the support provided by owner EQT since it took over the Belgium-based distributor together with PSP Investments earlier this year. The two funds revealed in June 2018 they were in exclusive negotiations to take over Azelis from private equity owner Apax Partners.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.